Pfizer (PFE) Liabilities and Shareholders Equity (2009 - 2026)

Pfizer has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $208.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.01% year-over-year to $208.0 billion; the TTM figure through Mar 2026 stood at $831.3 billion (down 3.01% YoY), while the FY2025 annual figure was $208.2 billion, down 2.45% from the prior year.
• Liabilities and Shareholders Equity held at $208.0 billion in Q1 2026, from $208.2 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PFE reached as high as $226.5 billion in Q4 2023 and fell as low as $41.1 billion in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $208.2 billion (2025), against an average of $199.1 billion.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 11.22% — and 2023, when it surged 422.64%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $197.0 billion in 2022, then grew by 14.98% to $226.5 billion in 2023, then declined by 5.79% to $213.4 billion in 2024, then retreated by 2.45% to $208.2 billion in 2025, then slipped by 0.08% to $208.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $208.0 billion, $208.2 billion, and $209.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.